Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities:
Net loss	$ (33,640,646)	$ (23,054,434)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	3,905,954	1,454,979
Issuance of common stock for services	378,204	68,000
Amortization of operating lease right-of-use asset	176,754	163,376
Depreciation	2,923	1,492
Deferred income tax expense	576,000
Gain from forgiveness of notes payable – paycheck protection program and accrued interest		(166,557)
Changes in operating assets and liabilities:
Prepaid expenses	(111,176)	(2,619,167)
Deposits		19,031
Accounts payable	(111,717)	(579,140)
Accrued expenses	783,434	457,920
Accrued compensation	(143,749)	251,081
Accrued interest		(87,996)
Operating lease liability	(177,237)	(158,999)
Net Cash Used In Operating Activities	(28,361,256)	(24,250,414)
Cash Flows From Investing Activities:
Purchase of property and equipment		(6,938)
Purchase of in-process research and development		(40,000,000)
Net Cash Used In Investing Activities		(40,006,938)
Cash Flows From Financing Activities:
Principal paid on notes payable – related parties		(172,970)
Proceeds from sale of NoveCite, Inc. common stock		500
Proceeds from common stock warrant exercises		31,130,134
Proceeds from common stock option exercises		82,634
Net proceeds from private placement		18,450,410
Net proceeds from registered direct offerings		70,979,842
Net Cash Provided By Financing Activities		120,470,550
Net Change in Cash and Cash Equivalents	(28,361,256)	56,213,198
Cash and Cash Equivalents – Beginning of Year	70,072,946	13,859,748
Cash and Cash Equivalents – End of Year	$ 41,711,690	$ 70,072,946